* Evolent Health, Inc. EVH.N reported quarterly adjusted
earnings of 2 cents per share for the quarter ended June 30,
higher than the same quarter last year, when the company
reported EPS of -10 cents. The mean expectation of
sixteen analysts for the quarter was for a loss of 2 cents per
share. Wall Street expected results to range from -11 cents to 1
cents per share.
* Revenue rose 46.9% to $652.52 million from a year ago;
analysts expected $598.00 million.
* Evolent Health, Inc.'s reported EPS for the quarter was a
loss of 25 cents.
* The company reported a quarterly loss of $28.36 million.
* Evolent Health, Inc. shares had fallen by 43.2% this
quarter and lost 23.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 25.2% in the last three months.
* In the last 30 days, two analysts negatively revised
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and the breakdown of recommendations is 11 "strong buy" or
"buy," 4 "hold" and no "sell" or "strong sell." The average
consensus recommendation for the advanced medical equipment &
technology peer group is also "buy"
* Wall Street's median 12-month price target for Evolent
Health, Inc. is $6.00, about 48.7% above its last closing price
of $3.08
This summary was machine generated from LSEG data August 6 at
02:16 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2026 -0.02 0.02 Beat
Mar. 31 2026 -0.05 -0.02 Beat
Dec. 31 2025 0.06 0.08 Beat
Sep. 30 2025 0.10 0.05 Missed